<DOC>
	<DOCNO>NCT00040729</DOCNO>
	<brief_summary>RATIONALE : Genetic test specific enzyme may help doctor determine whether side effect response chemotherapy relate person 's genetic makeup . PURPOSE : Genetic trial determine whether different form UGT1A1 gene relate body 's ability break drug gastrointestinal side effect see patient previously treat flavopiridol .</brief_summary>
	<brief_title>Genetic Study Patients Previously Treated With Flavopiridol Clinical Trial NCI-97-C-0171C</brief_title>
	<detailed_description>OBJECTIVES : - Determine relationship UGT1A1 genotypes drug pharmacokinetics occurrence gastrointestinal toxicity cancer patient previously treat flavopiridol protocol NCI-97-C-0171C . OUTLINE : Genomic DNA pre-existing sample serum plasma patient analyze UGT1A1 gene polymerase chain reaction DNA sequencing . Results analyze possible association UGT1A1 genotypic variation susceptibility flavopiridol . Patients receive result genetic testing , result influence type duration treatment . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cancer patient previously treat flavopiridol protocol NCI97C0171C PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>